Navigation Links
New agent may enhance effectiveness of radiotherapy
Date:5/13/2014

Scientists from The University of Manchester part of the Manchester Cancer Research Centre - have demonstrated the potential of a drug to improve the effectiveness of radiotherapy in stopping tumour growth.

There is increasing interest in using the body's own immune system to attack tumour cells a strategy that can be very effective without the side effects associated with conventional chemotherapy.

Skin cancers have been successfully treated using a topical cream, imiquimod, which recruits immune cells through a molecule known as toll-like receptor 7 (TLR7), a protein that recognises foreign and potentially harmful material.

Previously, researchers in Manchester have shown that they can also stimulate the immune system into generating an immune response against non-skin cancers by injecting an agent similar to TLR7 into the blood.

In collaboration with AstraZeneca and Dainippon Sumitomo Pharma, the Manchester group have looked at another molecule that activates TLR7, known as DSR-6434. Using mouse models of two different types of cancer, they investigated DSR-6434 on its own and in combination with radiotherapy and measured the effect on the primary tumour and the number of secondary tumours in the lungs.

Professor Ian Stratford, from Manchester Pharmacy School who, with Professor Tim Illidge, led the research published in the International Journal of Cancer, said: "We have already seen a strong immune system response from other immunotherapy agents in combination with radiation this new agent appears to be even more potent."

His team showed that administering DSR-6434 together with radiotherapy led to tumour shrinkage and increased long-term survival. They found that the combination treatment also reduced the occurrence of secondary lung tumours.

"It looks like there's good reason to use radiotherapy alongside immunotherapy agents in the treatment of solid tumours. These results strongly suggest that this sort of combination therapy should be evaluated in clinical trials with cancer patients," added Professor Stratford.


'/>"/>

Contact: Ali Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Pig stomach mucins are effective as anti-viral agents for consumer products
2. Imaging agents predict breast cancer response to endocrine therapy
3. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
4. New substances 15,000 times more effective in destroying chemical warfare agents
5. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
6. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
7. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
8. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
9. Rilpivirine for HIV: Added benefit for single agent proven
10. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
11. Investigational agent targets gene signaling pathways to improve response for patients with CLL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
Breaking Medicine Technology: